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Abstract
Introduction Tumors lack normal drainage of secreted fluids
andconsequently build uptumorinterstitial fluid (TIF). Unlike
other bodily fluids, TIF likely contains a high proportion of
tumor-specific proteins with potential as biomarkers.
Methods Here, we evaluated a novel technique using a
unique ultrafiltration catheter for in situ collection of TIF
and used it to generate the first catalog of TIF proteins from
a head and neck squamous cell carcinoma (HNSCC). To
maximize proteomic coverage, TIF was immunodepleted
for high abundance proteins and digested with trypsin, and
peptides were fractionated in three dimensions prior to mass
spectrometry.
Results We identified 525 proteins with high confidence.
The HNSCC TIF proteome was distinct compared to
proteomes of other bodily fluids. It contained a relatively
high proportion of proteins annotated by Gene Ontology as
“extracellular” compared to other secreted fluid and cellular
proteomes, indicating minimal cell lysis from our in situ
collection technique. Several proteins identified are putative
biomarkers of HNSCC, supporting our catalog’s value as a
source of potential biomarkers.
Conclusions In all, we demonstrate a reliable new tech-
nique for in situ TIF collection and provide the first
HNSCC TIF protein catalog with value as a guide for
others seeking to develop tumor biomarkers.
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Squamous cell carcinoma (SCC) is a common type of
cancer originating in epithelial cells. Survival rates of SCCs
of the upper respiratory tract 5 years post-diagnosis are
about 50% [1]. However, early detection and treatment
results in substantially better prognosis [1]. Currently, the
most accurate diagnostic test for all SCCs is a histological
examination of a tissue biopsy. A less invasive test that still
maintains sensitivity and selectivity, from a readily avail-
able bodily fluid like plasma or saliva, would be greatly
beneficial.
One potential test would be based on specific
differential protein expression, or protein biomarkers
of SCC. A promising source of possible biomarkers of
SCC is tumor interstitial fluid (TIF). The production of
TIF results from buildup of fluid derived from cell
secretions due to a lack of a fully formed vascular and
lymphatic system within the tumor [2]. Because this
fluid is directly associated with the tumor, it may be a
rich source of tumor-specific biomarkers. In the case of
SCC of the head and neck (and potentially SCC at other
anatomical locations), TIF may infiltrate other easily
sampled bio-fluids such as plasma or saliva. Thus,
knowledge of TIF proteomes may help to prioritize
putative protein biomarkers found in plasma or saliva to
guide validation studies.
Despite its potential value as a source of tumor
biomarkers, representative catalogs of TIF proteomes
are lacking. Contributing to this lack is the inherent
difficulty in effectively extracting TIF directly from
human subjects. Currently, a couple of different analysis
strategies for studying interstitial fluid have been
employed. First, some studies have used indirect
extraction of TIF from biopsies where resected tissue
is soaked in buffer and proteins diffused into the buffer
over time are analyzed [3, 4]. Other studies have used
cell culture models to study TIF-like proteomes where
conditioned media are collected after a period of
incubation and shed/secreted proteins are analyzed [5,
6]. These collections may not be true representations of
TIF due to the ex vivo and in vitro sampling techniques
employed.
In this study, TIF from a head and neck SCC tumor
was obtained directly in situ without biopsy using a
novel ultrafiltration catheter, and its proteome was
characterized via immunodepletion, trypsin digestion,
three-dimensional peptide fractionation, and mass spec-
trometry. This represents the first study of TIF collected
in situ and the first study of TIF obtained from head
and neck squamous cell carcinoma (HNSCC). Our
collection technique, sample preparation, and resulting
proteomic catalog should be a valuable resource to
others investigating tumor progression mechanisms as
well as those seeking to identify tumor-specific bio-
markers of SCC.
Experimental Methods
In Situ SCC TIF Collection TIF was collected from the
tumor of a patient with stage IV head and neck cancer with
informed consent using an ultrafiltration catheter previously
described [7]. Briefly, the catheter is constructed with
hollow fibers composed of polysulfone with 0.45-μm pores
throughout the walls of the fiber. This allows fluids and
prevents solid material from passing through. It is slightly
smaller than a 27-gauge needle, and the proximal shaft of
the catheter is the size of a 24-gauge needle to limit
disturbances from seeding. The proximal shaft is connected
to vacuum allowing for the extraction of fluid. TIF was
collected from the right and left side of the tumor, was
mixed with phosphate buffered saline, and was immediately
stored at −80°C. Protein amount was determined from BCA
assay (Pierce, Rockford, IL).
Depletion of High Abundance Proteins from TIF To
remove high abundance proteins from TIF for enhancement
of proteomic coverage, a Multiple Affinity Removal
System (MARS, Agilent Technologies, Inc., Palo Alto,
CA) column was used. The MARS column consists of
immobilized antibodies directed against albumin, IgG, IgA,
transferrin, haptoglobin, and antitrypsin. Protein from TIF
(0.4 mg) was applied to the MARS column, and the column
was used according to manufacturer’s instructions using
manufacturer-supplied buffers. Fractions consisting of
flow-through of unbound and eluted bound proteins were
collected separately. The flow-through fraction contained
0.15 mg of protein.
Trypsin Digestion and Fractionation of TIF Peptides Both
undepleted (100 μg) and MARS-depleted (150 μg) TIF
protein samples were independently digested and used for
proteomics analysis. As a denaturant, SDS was added to
TIF samples to a final concentration of 0.5% w/v.
Dithiothreitol (Sigma) was added at 10 mM and incubated
for 60 min at 56°C. Resulting free sulfhydryl groups were
alkylated with addition of 50 mM iodoacetamide (Sigma)
for 45 min at room temperature in the dark. Unreacted
iodoacetamide was neutralized with further addition of
40 mM dithiothreitol. Samples were diluted tenfold with
10 mM ammonium bicarbonate buffer (pH 8.0) to reduce
the SDS concentration to 0.05% w/v. Sequencing grade
trypsin (Promega, Madison, WI) was added to a final
enzyme/substrate ratio of 1:50, and the reaction was
incubated at 37°C overnight. The next day, samples were
76 Clin Proteom (2010) 6:75–82cleaned with an Oasis® MCX solid phase extraction
cartridge (Waters, Milford, MA) according to manufac-
turer’s protocol, and the eluted peptides were dried by
vacuum centrifugation.
Peptide isoelectric focusing (IEF) was performed using
an Agilent 3100 OFFGEL Fractionator (Agilent) [8] using
the 24-well setup with pH 3–10 IPG strips according to
manufacturer’s instructions. Briefly, peptides resulting from
trypsin digestion of TIF proteins were dissolved in 3.6 mL
of OFFGEL peptide sample solution consisting of appro-
priate ampholytes. The IPG strip was rehydrated with the
Peptide IPG Strip Rehydration Solution for 15 min. The
peptide solutions (either from the non-depleted or depleted
sample) were separately loaded in equal volumes (150 μL)
into each of the wells. The peptides were then electro-
focused at a maximum limit of 50 μA until 50 kVh was
reached. After completion, the peptide IEF fractions from
individual wells were collected. Peptide IEF fractions
from the non-deplet e ds a m p l e sw e r ea c i d i f i e dt op H~ 2
with TFA, purified using “Stage” tips [9] composed of
2×22-gauge needle punches of Empore™ extraction disks
(3 M, St. Paul, MN), dried by vacuum centrifugation, and
stored pending mass spectrometric analysis. The MARS
depleted samples were further fractionated with offline
strong cation exchange (SCX) HPLC as described previ-
ously [10].
Capillary LC-MS/MS Dried peptides were resuspended in
5 μL of load buffer (98:2:0.1 water/acetonitrile/formic
acid). Theses samples were loaded onto an in-house poured
reversed phase capillary column at 1,000 nL/min using an
Eksigent MicroAS autosampler and 1DLC nano-HPLC.
The column consisted of fused silica tubing packed with
Magic C18AQ—5-μm, 200-Å pore size resin (Michrom
Bioresources) to dimensions of 13 cm×100 μm, and the
outlet of the column was a pulled tip. Reversed phase
chromatography followed a gradient of 2–40% acetonitrile
in 0.1% formic acid over 90 min at 250 nL/min. The tip of
the column was in line with an LTQ-Orbitrap XL mass
spectrometer (ThermoFisher Scientific). Eluting solvent
was ionized using a nano-electrospray source. Spray
voltage was set to 1.75 kV, and the capillary ion transfer
tube was set to 160°C. Mass spectrometry was performed
using gas-phase fractionation as described elsewhere [11].
A series of four separate full scans were acquired from the
orbital trap (m/z 380–520; 515–690; 685–975; 970–2,000)
at a resolution of 60,000 at m/z 400 with AGC settings of
1E6 ions or 500 ms. The top three intense ions from each
individual full scan fraction were subjected to fragmenta-
tion by CID at a normalized collision energy of 35% and
scanned out using the LTQ ion trap. AGC settings for the
LTQ ion trap were 1E4 ions or 100 ms. Charge state
screening was enabled for full scans so that unassigned
charge states and singly charged ions were rejected for CID.
Ions previously selected for CID were also excluded from
further analysis using dynamic exclusion. The exclusion list
was set to the maximum default value of 500 entries.
Exclusion time was set to 60 s with a mass tolerance
window of −0.6 to 1.2 amu. Spectral data were acquired
and saved using Xcalibur software.
Cheek Cell Brush Biopsy Collection and Analysis The
inside of the cheek of a healthy volunteer was dried with a
cotton swab to minimize salivary contamination, and buccal
epithelial cells were obtained with brushing using an
OralCDx brush test kit (OralCDx Laboratories, Inc.,
Suffern, NY). The inner cheek was brushed ten times in a
consistent direction. After that, the oral brush was rotated
360° for three times on the tissue surface. The applied
pressure was just enough to slightly bow the handle of the
brush. The brush head was placed in 0.25 mL of lysis
buffer (4% SDS, 10% 2-mercaptoethanol, 100 mM Tris–
HCl, pH 6.8, and 1× protease inhibitors (Complete Mini,
Roche Applied Science, Indianapolis, IN, USA)), and the
exfoliated epithelial cells were lysed with continuous
vortexing for 15 min at room temperature. The protein
lysate (0.25 mL) was chilled on ice prior to addition of 1 mL of
ice-cold acetone to precipitate proteins overnight at −20°C.
Precipitated protein was centrifuged at 6,000 rpm for 10 min at
4°C, and the protein pellet was dissolved in 50 mM Tris–HCl,
pH 8.5 containing 5 mM EDTA. An aliquot containing 0.1 mg
of protein was digested with sequencing grade trypsin
(Promega, Madison, WI) at a 1:100 enzyme/substrate ratio.
Digestion occurred overnight at 37°C, and resulting peptides
were subjected to SCX as described above. A total of nine
fractions were analyzed by reversed phase nLC MS/MS
essentially as described [10]
Database Searching and Data Processing Mass spectral
data were searched using MaxQuant software [12]. MSM
files were generated using the Quant feature. Parameters
included full trypsin specificity with up to two missed
cleavages and oxidized methionine as a variable modifica-
tion. The TIF data also included Cys alkylation as a fixed
modification. The MSM files were searched against a
composite of the IPI human database v3.52 and its reversed
compliment including common contaminant proteins using
Mascot [13] with 7 ppm precursor and 0.5 amu fragment
ion mass tolerances, respectively. Identification parameters
included minimum PEP score of 1, at least two unique
peptides for identification, and protein false discovery rate
(FDR) <1%.
Comparison of TIF to Other Proteomes The salivary
protein dataset was generated from .raw files obtained from
[10] and was searched using MaxQuant and parameters as
Clin Proteom (2010) 6:75–82 77above. It contained 2,096 proteins identified from two or
more unique peptide sequences. Plasma proteins were
obtained from publicly available Human Plasma Proteome
Project, http://www.bioinformatics.med.umich.edu/hupo/
ppp. This dataset contained 3,020 proteins which were
identified with at least two unique peptides. Protein datasets
from conditioned media of the ovarian cancer cell lines:
HTB-75, RMUG-S, TOV-112D, and TOV-21G were
obtained from [5]. Identifications were filtered based on
95% peptide probability and 80% protein probability for
PeptideProphet [14] and ProteinProphet [15], respectively.
The liver interstitial fluid (IF) proteomes were from [4], and
each identification had at least two unique peptide matches.
Proteomic comparisons were accomplished through match-
ing of IPI accession numbers.
Comparison Using Gene Ontology Terms Proteins identi-
fied from TIF and epithelial brush biopsy cell lysate were
compared by the cellular components Gene Ontology (GO)
term. The resulting MaxQuant identification output
contained Gene Ontology names corresponding to each
protein. Names that included “cytosolic,”“ cytoplasmic,” or
“cytoskeletol” were counted and grouped as “cytoplasmic.”
Names that referred to organelles such as the endoplasmic
reticulum, the nucleus, mitochondria, the Golgi complex,
peroxisomes, or lysosomes were counted and grouped as
“organellar.” Proteins without term information or with no
apparent location were grouped as “unclassified.” Several
proteins grouped into multiple categories.
Results
In Situ Collection of TIF For our study, a unique ultrafiltra-
tion catheter [7, 16] was used for in situ TIF collection from
a patient with a stage IV neck SCC. The catheter, originally
designed to deliver therapeutics to localized sites, was
composed of a fibrous wall 3-mm long with an outer
diameter of 380 μm similar to that of a 28-gauge needle.
The walls were made of semi-permeable hydrophilic
polysulfone fiber with 0.45-μm pores to prevent solid
material from passing through. The porous fiber also had a
relatively large surface area to dissipate the force generated
from suction, thereby providing gentle extraction. In all, the
miniature design with large surface area was intended to
limit tissue damage. The distal end was enclosed, and the
proximal end was connected to a Vacutainer, providing
suction for removal and storage of the TIF.
Sample Preparation and Proteomic Analysis of TIF TIF
was collected from two bilateral regional metastases of a
stage IV HNSCC in a single patient with informed consent.
The extracted fluids were mixed with phosphate-buffered
saline and immediately stored at −80°C until further use.
The total protein amount extracted was 0.6 mg according to
BCA assay. The Coomassie staining pattern after SDS-
PAGE showed that the two TIF collections were very
similar (Fig. 1, lanes 1 and 2), suggesting that the TIF was
homogenous throughout the tumor and that extraction was
consistent and repeatable. The detection of only a few
intense bands by Coomassie staining indicated the possible
presence of several proteins at much higher abundance
compared to other proteins in the sample, similar to the
large dynamic range of protein abundances observed in
other bio-fluids like plasma.
To get an initial assessment of the protein composition
of TIF, a small portion was digested with trypsin, and the
peptides were analyzed via tandem mass spectrometry
(MS/MS). The seven identified proteins that had the
highest number of assigned spectra (starting with the
highest in descending order) were albumin, hemoglobin
(beta and alpha subunits), transferrin, complement com-
ponent 3 precursor, haptoglobin isoform 2 preprotein,
alpha-2-macroglobulin, and alpha-1-antitrypsin. Consis-
tent with these results, the most prominent bands in
Fig. 1 at ~70 and ~15 kDa match the expected molecular
weight of albumin and alpha/beta globin, respectively.
Except for the two hemoglobin subunits, the other six
proteins are among the most abundant proteins found in
plasma [17, 18].
Seeking to expand our identification of lower abundance
proteins, we chose to remove the high abundance proteins
through immunodepletion using a MARS column designed
to remove the abundant plasma proteins we found in TIF.
After starting with ~0.4 mg, the depleted flow-through from
Fig. 1 SDS-PAGE analysis of
TIF. TIF (10 μg) was separated
by SDS-PAGE and stained with
Coomassie brilliant blue. The
two lanes labeled right and left
represent TIF collected from
two separate extractions using
the ultrafiltration catheter device
of a head and neck tumor in situ
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These proteins were digested with trypsin, and the peptides
were separated based on isoelectric point. We then
incorporated SCX chromatography as depicted in Fig. 2,
which outlines the sample preparation and analysis scheme.
SCX had previously been shown to be an effective second
fractionation step after isoelectric focusing for complex
samples [10, 19]. Specifically, the isoelectric point peptide
fractions were combined in groups of six to eight fractions
creating three separate pools, each of which was subjected
to SCX HPLC. A total of 12–15 fractions from each pooled
sample were selected based on signal from UV chromato-
grams of the associated SCX fractionation [10]. Each of
these fractions was individually subjected to μLC-MS/MS
analysis, which resulted in identification of 525 proteins
with at least two unique peptide sequences. The global
protein level FDR was <1%. All of the identified peptides
are listed in Supplementary Table 1, and the corresponding
proteins are listed in Supplementary Table 2.
Comparison of HNSCC TIF to Other Proteomes With a
novel, high confidence protein catalog in hand, we next
sought to compare it with other proteomes to further
characterize the HNSCC TIF proteome. Since HNSCC
TIF contained several high abundance plasma proteins, we
initially compared it against the plasma proteome to
determine the degree of similarity between these two
proteomes. The human plasma proteome was obtained
from the HUPO Plasma Proteome Project (http://www.
bioinformatics.med.umich.edu/hupo/ppp) and contained
3,020 proteins with at least two unique peptide identifica-
tions. Unexpectedly, HNSCC TIF had a relatively small
overlap of common proteins with plasma (40% overlap,
Fig. 3a) .I nf a c t ,H N S C CT I Fs h a r e dm o r ei nc o m m o n
with the proteome of whole saliva (76% overlap,
Fig. 3b). This finding was even more striking considering
that the plasma proteome had about 1,000 more proteins
than saliva. The relatively low amount of overlap with
plasma supported that the HNSCC TIF was collected with
little or no accidental contamination from blood. Thus, the
ultrafiltration catheter appeared to avoid damage to blood
vessels.
We next sought a more direct comparison of the HNSCC
TIF proteome to other IF or IF-like proteomes. Recently,
the proteomes of liver tissue IFs were reported [4]. The IFs
were derived from tissue biopsies and obtained ex vivo
from proteins released into buffer. These samples included
TIF from a hepatocellular carcinoma (HCC), IF from a non-
tumor part of the same liver, and IF from a separate healthy
liver. Not surprisingly, the HCC TIF proteome had the most
in common with the HNSCC TIF proteome with 41%
overlap (Fig. 3c), whereas the IF from a non-tumor part of
Fig. 2 Proteomic analysis strategy for identifying proteins from TIF.
High abundance proteins in TIF were removed using a MARS
column. Remaining proteins were digested with trypsin to generate
peptides. The peptides were subjected to three dimensions of
fractionation using isoelectric focusing, strong cation exchange
chromatography, and reversed-phase chromatography prior to tandem
mass spectrometry analysis. MS/MS data was searched against a
human database using MaxQuant
Fig. 3 Comparison of proteins identified in TIF to other proteomes.
Venn diagrams showing common and unique proteins from HNSCC
TIF to a plasma, 40% in common; b saliva, 76% in common; c
hepatocyte cell carcinoma TIF, 41% in common; and d conditioned
media from TOV-112D ovarian carcinoma cell line, 34% in common
Clin Proteom (2010) 6:75–82 79the same liver and the IF from a separate healthy liver had
38% and 35% of proteins in common. Even though there
was 41% overlap, the HCC and HNSCC TIF proteomes
had large numbers of non-shared proteins suggesting that
they were quite distinct.
Finally, the HNSCC TIF was compared to secreted
proteins from four different ovarian cancer cell lines.
The proteomic datasets were obtained in a previous
study [5] where an extensive analysis was performed
using conditioned media after incubation with cells in
order to obtain shed or secreted proteins, similar in
principle to those found in TIF. This type of rigorous
proteomics analysis has not been performed for HNSCC-
based cell models, and despite differences, an ovarian
cancer model seemed appropriate since both cancer types
are epithelial in nature. HNSCC TIF had 34% proteins in
common with media from TOV-112D cells (Fig. 3d).
There was somewhat less overlap with media from HTB-
75 cells (28%), TOV-21G cells (29%), and RMUG-S
(18%; data not shown). Once again, the HNSCC TIF
proteome had a high amount of non-overlapping proteins
further demonstrating that our in situ collected HNSCC
TIF proteome was distinct.
Cellular Localization of HNSCC TIF Proteins
The identified HNSCC TIF proteins were classified
according to the Gene Ontology term “cellular compo-
nents” to determine cellular localizations. Proteins associ-
ated with the cytoskeleton were grouped in “cytoplasmic,”
and proteins associated with the endoplasmic reticulum,
Golgi complex, mitochondrion, lysosome, peroxisome, or
nucleus were grouped as “organellar.” In cases of ambigu-
ity, proteins were grouped into more than one category. In
order to assess potential cell lysis caused by our in situ
collection technique, the cellular localization of the
HNSCC TIF proteome (525 proteins) was compared to a
similar sized proteome (524 proteins) identified from lysed
cells gathered from brushing the cheek buccal epithelium of
a healthy volunteer (Fig. 4). If our collection technique
caused a significant amount of cell lysis, we expected that
the HNSCC TIF proteome would show a similar proportion
of cytoplasmic and organellar proteins as compared to the
epithelial cell proteome. As expected, the cellular lysate
contained a large amount of cytoplasmic (421) and
organellar (374) proteins, whereas only 61 proteins were
classified as extracellular. On the other hand, HNSCC TIF
proteome had lower amounts of proteins classified as
cytoplasmic and organellar, 339 and 269, respectively, but
a comparatively higher proportion of proteins grouped as
extracellular (203 total). The overall percentage of proteins
grouped as extracellular for HNSCC TIF was high even
compared to known extracellular fluids like saliva (data not
shown). In all, this data was in agreement with a low level
cell lysis associated with the HNSCC TIF sample.
Potential Protein Biomarkers Found in HNSCC TIF The
proteins of HNSCC TIF were examined to see if any had
been previously reported as a potential biomarker for
HNSCC. In a recent review, Schaaij-Visser et al. [20]
compiled a list of putative biomarkers for SCC from several
different proteomics-based studies. The list, shown in
Table 1, was modified to contain biomarkers specific for
cancer or cancer progression, which came from in vivo
sources of bio-fluid and were up-regulated compared to
healthy states. We identified several putative up-regulated
protein biomarkers that were identified in HNSCC TIF.
Some were identified with several unique peptides and high
sequence coverage such as catalase (60% coverage),
S100A9 (56.1% coverage), and profilin (59.3% coverage).
This suggests that TIF may be a bountiful source of tumor-
related biomarkers.
Conclusions
This study describes the first report to our knowledge of
the proteomic characterization of HNSCC TIF. It is also
the first report of proteomic analysis of TIF obtained in
situ. Initial characterization showed that HNSCC TIF
had a large dynamic range of protein abundance (see
Fig. 1). Many of the high abundance proteins were the
same high abundance proteins found in plasma. As a
result, we chose to use MARS depletion coupled with
Fig. 4 Comparison of HNSCC TIF and healthy buccal epithelial cell
lysate from brush biopsy using the cellular components Gene
Ontology term. Identified proteins of HNSCC TIF (solid bars) and
epithelial cell lysate (open bars) were categorized into different
cellular localizations. Proteins with names associated with cytosol or
cytoskeleton were grouped as cytoplasmic. Proteins with localizations
for the nucleus, mitochondria, the endoplasmic reticulum, the Golgi
complex, peroxisomes, or lysosomes were grouped as organellar.
Several proteins were grouped into more than one bin. Proteins with
no Gene Ontology information or no clear localization were grouped
as unclassified
80 Clin Proteom (2010) 6:75–82three-dimensional peptide fractionation in our sample
preparation, which enabled deeper proteomic coverage.
The scheme employed here, as depicted in Fig. 2,m a y
serve as a template for future TIF proteomic studies. In
all, 525 proteins were identified with high confidence.
As a whole, our results indicated that the ultrafiltration
catheter effectively collected TIF in situ and preserved its
integrity by limiting contamination from other sources.
First, SDS-PAGE analysis of two separate collections of
TIF from the same tumor showed that each collection was
consistent. If the samples were contaminated with proteins
due to cell lysis or blood vessel damage, we would have
expected more random protein patterns detected between
the samples. Second, HNSCC TIF identified proteins had a
relatively small overlap to proteins identified from plasma
(Fig. 3a). This demonstrated that the catheter did not
accidentally damage blood vessels leading to introduction
of blood proteins into our sample. Third, grouping of
protein identifications based on the “cellular components”
Gene Ontology term revealed that the TIF proteome had a
high proportion of proteins grouped as extracellular and a
low proportion of proteins classified as cytoplasmic and
organellar compared to a similar sized dataset of an
epithelial cell lysate (Fig. 4). The localization of proteins
identified from TIF was consistent with that of an
extracellular fluid and further suggested that the insertion
of the catheter caused minimal cell damage.
The TIF proteome characterized here was quite distinct
when compared to other relevant proteomes as shown in
Fig. 3. There was a relatively low overlap of identified
proteins when compared to interstitial fluids derived from
liver andwhencomparedtoproteinssecretedintoconditioned
media from various ovarian cancer cell lines. Part of the low
overlap is likely due to the different biological sources of the
fluids.However, thedistinctiveness ofthe HNSCCTIF isalso
probably a result of the unique sample collection technique.
Previous studies of TIF have relied on excision of tissue
biopsies followed by soaking of the extracted tissue over time
inbuffer.Thismethodiscomparablyquitedestructiveandhas
invariably led to identification of contaminating proteins,
which may negatively affect biomarker studies. The unique
technique used in this study allowed for gentle collection of
TIF in situ, without a biopsy or time delay. Overall, our in
situ technique reliably collects high fidelity TIF samples, and
it should prove beneficial for further studies characterizing
fluid from other types of tumors.
TIF protein catalogs obtained from high fidelity samples,
such as the HNSCC catalog presented here, have potential
value in prioritization of potential biomarkers found in
other studies. There has been a large push in the field of
proteomics to find protein biomarkers from easily accessible
fluids such as plasma or saliva. Numerous potential bio-












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Clin Proteom (2010) 6:75–82 81proteomics discovery studies. It is difficult to validate all
of these potential biomarkers because each validation
requires it own specific and sensitive test, which together
is rate-limiting. Consequently, prioritization is usually
necessary, enabling validation of the most promising
potential biomarkers. Given the rich source of potential
biomarkers provided by the catalog of TIF proteins, it
should serve as a valuable guide to help prioritize
potential biomarkers discovered in other bodily fluids
for validation. Indeed, a number of proteins identified in
our study were previously sho w nt ob eu p - r e g u l a t e di n
SCC progression (Table 1). Thus, our TIF protein catalog
should be beneficial for future biomarker studies.
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